Cita APA

Bennouna, J., Hiret, S., Bertaut, A., Bouché, O., Deplanque, G., Borel, C., . . . Borg, C. (2018). Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol.

Citación estilo Chicago

Bennouna, Jaafar, et al. "Continuation of Bevacizumab Vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial." JAMA Oncol 2018.

Cita MLA

Bennouna, Jaafar, et al. "Continuation of Bevacizumab Vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial." JAMA Oncol 2018.